Table 2 Risk of long-term adverse outcomes by CID status in TORCH and ECLIPSE [48]
From: Measuring disease activity in COPD: is clinically important deterioration the answer?
Outcome | TORCH (n = 5292) | ECLIPSE (n = 1953) | ||||
|---|---|---|---|---|---|---|
CID+ at 6 months [N = 2870], n (%) | CID- at 6 months [N = 2422], n (%) | % risk increase assessed at 7–36 months (95% CI) | CID+ at 12 months [N = 1442], n (%) | CID- at 12 months [N = 531], n (%) | % risk increase assessed at 13–36 months (95% CI) | |
Moderate/severe exacerbation | 2082 (73) | 1450 (60) | 61 (50, 72) | 1082 (75) | 232 (44) | 154 (120, 193) |
Hospital admission for severe exacerbations | 797 (28) | 491 (20) | 55 (38, 73) | 454 (31) | 66 (12) | 181 (117, 263) |
All-cause mortality | 237 (8) | 160 (7) | 41 (15, 72) | 121 (8) | 27 (5) | 59 (4, 141) |